Long noncoding RNA ENST00000508435 promotes migration of breast cancer via FXR 1

Luying Li, Youping Jin*, Xue Wang, Li Wang, Yangbai Sun, Yihong Luo, Xiaojian Ni, Qi Lu, Wenbo Wei, Xiuling Zhi, Jerry Yu, Wei Zhu, and Ping Zhou

*Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, China; 1Institutes of Biomedical Sciences, Fudan University, Shanghai, China; 1Pudong Hospital, Fudan University, Shanghai, China; 1Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Fudan Medical College, Fudan University, Shanghai, China; 1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; 1Department of Medicine, University of Louisville, Louisville, KY, USA

ABSTRACT
LncRNA plays a critical role in tumor progression. However, the role it executes in breast cancer is still unclear. Here, we report a newly discovered lncRNA, ENST00000508435, which could be remarkably up-regulated in breast cancer cells and tissues. We found that the expression of ENST00000508435 was positively correlated with tumor size, lymph node metastasis and HER2. More interesting, overexpression of ENST00000508435 significantly increased cell migration, while specific knockdown led to the opposite. RNA pull-down and RNA immunoprecipitation assays demonstrated that ENST00000508435 could directly bind to FXR1 to promote tumor metastasis. ENST00000508435 and FXR1 were positively correlated. FXR1 was also significantly up-regulated in breast tumors. Taken together, we propose that ENST00000508435 regulates FXR1 to promote breast cancer metastasis.

Introduction
Breast cancer, with high metastasis and lethal characteristics, has lately been reported to surpass lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung cancer (11.4%) in the world [1]. Although its clinical intervention has been improved in recent years, the prognosis still remains unsatisfactory, and molecular mechanisms of its metastasis remain unrevealed. Therefore, there is an urgent need to determine its underlying mechanisms to provide novel targets for prevention and/or treatment of breast cancer.

The human genome can express more than 100,000 proteins via transcription and translation. Only 2% of our genomic transcripts can encode proteins. The rest are noncoding RNAs (ncRNAs). The ncRNAs can be divided into two types according to RNA length: small RNA (<200bp) and long non-coding RNAs (lncRNAs) (>200bp) [2]. Based on the genetic location and transcriptional direction, LncRNAs can be further divided into: sense lncRNAs, antisense lncRNAs, intergenic lncRNAs and divergent lncRNAs [3]. Most lncRNAs are transcribed by RNA polymerase II, with 5’ methyl cap and 3’ polynucleotide tail [3]. Reportedly, lncRNAs interact with DNAs, proteins and other RNAs, and participate in the processes of transcriptional, post transcriptional and epigenetic levels [4]. LncRNAs are responsible for tumorigenesis, and play pivotal roles in tumor cell proliferation, apoptosis, migration and invasion [4]. Using microarray, we previously identified a number of lncRNAs that were aberrantly expressed in breast cancer tissues [5]. Nevertheless, the expression and function of lncRNA ENST00000508435 in breast cancer have not been studied intensively.

In the present study, we hypothesize that ectopic lncRNA ENST00000508435 involves breast cancer progression. To begin with, quantitative real-time PCR was executed to validate the expression of lncRNA ENST00000508435 in breast cancer cell lines and tumor tissues. We found that it was significantly higher in both breast tumor cells and tissues than those in normal breast epithelial cells and peritumor

CONTACT Ping Zhou zping@shmu.edu.cn Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, No. 130 Dongan Road, Shanghai 200032, China; Wei Zhu zhuwei1@zs-hospital.sh.cn Department of General Surgery, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China
*These authors contributed equally to this work.
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
tissues, respectively. Together with some experimental results, we figured out that the ectopic ENST00000508435 was associated with tumor size, lymph node metastasis and HER2 in breast cancer patients. In addition, we used RNA pull-down assay, RNA immunoprecipitation (RIP) to explore the target protein of ENST00000508435 in the metastasis. At last, we performed in vivo experiments to confirm the function of ENST00000508435 in breast cancer metastasis.

Materials and methods

Tumor tissues and cell lines

This study was carried out in accordance with the World Medical Association Declaration of Helsinki and approved by the Basic Medical Ethics Committee of Fudan University (2017-F001). All 127 pairs of fresh breast cancer tissues and matched paracancerous tissues were collected from Zhongshan Hospital, Fudan University. The hematoxylin–eosin-stained frozen sections contained more than 70% of sufficient epithelial elements. The human breast cancer cell lines MDA-MB-231 (RRID: CVCL_0062), BT549 (RRID: CVCL_1092), MCF-7 (RRID: CVCL_0031) and T47D (RRID: CVCL_0553) were obtained from Shanghai Type Culture Collection of the Chinese Academy of Sciences. Human mammary epithelial cell lines MCF10A (RRID: CVCL_0598) were purchased from the American Type Culture Collection. Human mammary epithelial cell lines MCF10A were purchased from the American Type Culture Collection. BT549 and T47D were routinely cultured in RPMI-1640 medium supplemented with 10% FBS (Gibco, Grand Island, NY). MDA-MB-231 and MDA-MB-468 were cultured in L-15 medium (Gibco, Grand Island, NY, Grand Island, NY) with 10% FBS without CO2. MCF-7 cell lines were maintained in DMEM (high glucose) (Gibco, Grand Island, NY) supplemented with 10% FBS. MCF10A cell lines were maintained in F12 medium (Gibco, Grand Island, NY) supplemented with insulin (10 mg/mL; Sigma), EGF (100 mg/mL; Sigma), hydrocortisone (1 mg/mL; Sigma), choleretic toxin (100 ng/mL; Sigma), and 5% horse serum (Gibco, Grand Island, NY). All cells were supplemented with 100 U/mL penicillin G and 100 μg/mL streptomycin (Gibco, Grand Island, NY).

Real-time quantitative PCR assay

Total RNA for cell lines was harvested with Trizol (Life Technologies, Rockville, MD) according to the manufacturer’s instructions. RNA was reversely transcribed to cDNA using PrimeScript RT reagent kit (Toyobo, Japan). The cDNA was amplified with a CFX96 real-time PCR system (Bio-Rad, Hercules, CA) using SYBR Green PCR Master Mix (Bio-Rad) to determine the transcription level of specific genes. GAPDH was used for normalization. The expression level of objective RNA was calculated by the 2−ΔΔCt method. Primer sequences applied were as follows: GAPDH, (F: 5’-GGG AAA CTG TGG CGT GAT-3’, R: 5’-GAG TGG GTG TCG CTG TTG A-3’); ENST00000508435-1, (F: 5’-GAG AAG GAT GAG CAC ACT G-3’, R: 5’-ATC AAC AGG ACC TCT GGA T-3’); ENST00000508435-2, (F: 5’-ATC AAT TCT ATA ATT CCC TCC TTC CTC-3’, R: 5’-AAC CAC TTA TTT CTC CAT CCT TTG C-3’); FXR1, (F: 5’-ACG AGC TGA GTG ATT GGT CA –3’, R: 5’-CTG TGA TGA GAT TCG CTG GC-3’).

Western blot

Cells were washed twice in cold phosphate-buffered saline solution (PBS) and lysed in ice-cold RIPA buffer containing protease inhibitors and phosphatase inhibitors. Equal amounts of proteins were separated with 6%–12% SDS-PAGE gel and blotted onto polyvinylidene fluoride membranes. The membranes were blocked 1–2 h at room temperature with 5% skim milk and incubated with primary antibodies against FXR1 (Abcam Cat# ab56386, RRID: AB_2110688) and β-actin (Santa Cruz Biotechnology Cat# sc-47,778, RRID: AB_626632) at 4°C overnight, followed by PBS Tween wash. The samples were incubated with secondary antibodies for 1–2 h at room temperature, and protein bands were then visualized with Quantity One software (Bio-Rad). The expression level was normalized with β-actin.

Plasmid and siRNA transfection

The full length of cDNA encoding ENST00000508435 was PCR-amplified with primers and inserted into the BamHI and XhoI sites of the pcDNA3.1 vector named pcDNA-ENST00000508435. The siRNAs to target ENST00000508435, FXR1, and nonspecific controls were constructed by GenPharma (Shanghai, China). Transfections were performed with Lipofectamine 2000 (Invitrogen, CA) in Opti-MEM (Gibco, Grand Island, NY) according to the manufacturer’s instructions. Cells were harvested after 48 h. The siRNA sequences follows: ENST siRNA-homo-358 (sense 5’-GCC AGA GAA GGA GGA UAA GCA CTT-3’, antisense 5’-GCC AGA GAA GGA UAA GCA CTT-3’); ENST siRNA-homo-317 (sense 5’-GAG AUA AGA GAG GCA CAA ATT-3’, antisense 5’-UUA GUG CCU CUC UAU UCU CTT-3’); ENST siRNA-homo-215
(sense 5'-GCA AAG GAU GGA GAA AUA ATT-3', antisense 5'-UUA UUU CUC CAU CCU UUG CTT-3'); and FXR1 siRNA (sense 5'-GCA AAU GAC CAA GAG CCA UTT-3', antisense 5'-AUG GCU CUU GGU CAU UUG CTT-3').

**Cell fractionation assay**

The cell fractionation assay was performed by the Paris Kit (life, Part Number AM1921, Grand Island, NY) according to the manufacturer's instructions. In brief, up to 10⁷ fresh cultured cells, resuspended in 300 to 500 µL ice-cold cell fractionation buffer, and incubated on ice for 5 to 10 min; after centrifugation, the nuclear pellet was lysed in cell disruption buffer, mixed with 2× lysis/bindng solution and ethanol, and washed; RNA was then eluted.

**Transwell migration assay**

To test cells' migratory ability, transwell migration experiment was performed in 8-µm-pore transwell inserts (Corning Costar, Cambridge, MA). Therein, 0.5 × 10⁵ cells were seeded in the upper chamber in serum-free medium. Add medium containing 10% FBS as a chemoattractant to the lower chamber. After incubating for 24 h, wiped the cells that failed to migrate through the pores with a cotton swab, fixed the filter membrane with 4% paraformaldehyde, and stained with 0.1% crystal violet. Cell numbers were counted and analyzed in six random fields per well.

**Wound healing assay**

pcDNA-ENST00000508435 and siRNA were transiently transfected into MDA-MB-231 and BT549 cells in 6-well plates. After 48 h, when the cells at approximately 90% confluence, scraped the cell monolayer with a 200-µL pipette tip to create a wound gap. The wounded monolayers were then washed with PBS and cultured for various amounts of time. Five fields were randomly selected in each scratch wound, and the scratches were photographed microscopically. The gap lengths were measured with Image J software. Overexpression of ENST00000508435 in the MDA-MB-231 cells and the scraped cells was monitored by a JuI Smart fluorescent cell analyzer. The movement of cells was observed in the same field of view, and photographs were taken every 20 min for 36 h.

**RNA pull-down**

LncRNA ENST00000508435 or antisense lncRNA ENST00000508435 were transcribed in vitro from vector pcDNA3.1 and biotin-labeled T7 RNA polymerase (Roche, Basel, Switzerland) using Biotin RNA Labeling Mix (Roche). Biotinylated RNAs were dissolved with RNase-free DNaseI (Roche) and purified with an RNeasy Mini Kit (Qiagen, Valencia, CA). Whole-cell lysates (1 mg) from BT549 cells were then incubated with 3 µg of purified biotinylated transcripts at 4°C for 1 h. Washed streptavidin agarose beads (Invitrogen) were added to the protein-RNA complexes and incubated at room temperature for 1 h, washed three times, and boiled at 95°C in SDS buffer. The protein was then detected via SDS gel electrophoresis.

**RNA immunoprecipitation**

RIP was performed with the Magna RIP RNA-binding protein immunoprecipitation kit (Millipore, Bedford, MA) and FXR1 (CST, Beverly, MA) according to the manufacturer's instructions. In brief, beads were mixed with IgG or FXR1 antibody and cell lysate, rotated at room temperature for 4 h, and washed five times. The co-precipitated RNAs were detected via RT-qPCR.

**Microfluidic chip invasion assay**

A microfluidic device with various microchannels was used to mimic the invasion and migration process in vivo. The system comprised a PDMS (polydimethylsiloxane; Corning, NY)–glass device connected with a syringe pump and a Petri dish. It contained several micro channels for functions such as culture medium supply, cell seeding, and Matrigel (Corning) loading. Briefly, cells were seeded into the cell culture channel of the microfluidic chip at a density of 5 × 10⁴ cells/cm² with a medium containing 10% FBS. The chip was then turned on its side to allow the cells to adhere to the surface of the gel. The cells were allowed to invade for 12 h to evaluate their invasion abilities, and DAPI was applied to stain the nuclei.

**Animal studies**

MDA-MB-231 cells (2 × 10⁶) with ENST00000508435 overexpression and control vectors were respectively resuspended in 100 µL of PBS, and then were injected into the tail veins of 8-week-old female BALB/c nude mice (eight mice in each group) to generate metastasis, respectively. Four weeks later, the mice were euthanized with an overdose of anesthetic. The mice were first anesthetized via subcutaneous injection of
pentobarbital sodium. The initial dose given to mice was 65 mg/kg, and an additional 3-mg dose would be given according to actual experimental needed. The metastatic burden in the lungs was quantified from four hematoxylin–eosin-stained sections. All animal experiments were performed in the Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University. Related animal studies were followed National Institutes of Health guide for the care and use of Laboratory animals. The protocol and procedures employed were ethically reviewed and approved by the Institutional Animal Care and Use Committee at Fudan University (20160927–4).

**Statistical analysis**

Data were analyzed with SPSS 17.0 (Chicago, IL, USA). Two-tailed student's t-tests or one-way ANOVA were used. A P value of less than 0.05 was considered for a significant influence. The diagrams were processed with Prism 6.0 (GraphPad Software, La Jolla, CA, USA).

**Results**

**Expression of ENST00000508435 increases in human breast cancer tissues and cell lines**

We previously reported that in breast cancer tissues, 224 lncRNAs were upregulated and 324 lncRNAs were down-regulated compared to para-carcinoma tissues (NCBI GEO accession: GSE80266) [5]. Further analyses of our previously constructed microarray data showed that the expression level of lncRNA ENST00000508435 was significantly upregulated in breast cancer tissues, compared with that in paracarcinoma tissues. We performed RT-qPCR assays to measure the relative expression of ENST00000508435 in 127 clinical breast cancer tissues (paired peritumor as control) and breast cancer cell lines (MCF10A versus BT549, MCF-7, MDA-MB-231 and T47D). ENST00000508435 expressed significantly higher in both breast cancer tissues and cell lines (Figure 1(a, b)). Cellular fractionation assay shows that lncRNA ENST00000508435 was mostly localized in the nuclei of breast cancer cells (Figure 1(c)).

**ENST00000508435 is related to tumor size, lymph node metastasis and HER2**

To characterize the role of ENST00000508435 in breast cancers, we investigated the relationship between the expression of ENST00000508435 and some typical clinical pathologic parameters (tumor size, breast cancer biomarkers (ER, PgR, and HER2), lymph node metastasis, ki67 and Nottingham grade). We found that the expression of ENST00000508435 was positively correlated with tumor size, lymph node metastasis and HER2 (Supplementary Table 1).

**Ectopic expression of ENST00000508435 intensively promotes breast cancer cell migration**

To assess the biological function of ENST00000508435, we examined the impact of ENST00000508435 expression level on the migration of breast cancer cells with cell transwell assays and wound healing. The full length of pcDNA-ENST00000508435 cDNA was transfected into breast cancer MDA-MB-231 cells by plasmid vectors. The expression was significantly increased about 200 times (Figure 2(a)). Transwell migration and wound healing assay showed that ectopic expression of ENST00000508435 prominently increased the migration of MDA-MB-231 cells (Figure 2(b, c)). In addition, the movement of MDA-MB-231 cells was detected by Jull fluorescent cell analyzer (Figure 2(d)). Conversely, we performed reciprocal experiments to study the effects of knockdown on the migration in BT549 cells, which express high levels of ENST00000508435. Expression of ENST00000508435 was notably down regulated upon specific siRNA transfection (Figure 2(e)). Furthermore, down-regulation of ENST00000508435 expression impaired all migration capacity (Figure 2(f,g)).

**Association of ENST00000508435 and Fragile X-Related 1 gene (FXR1)**

LncRNAs exert important roles in regulating cell processes by binding with proteins. Recent research have reported that lncRNA HOTAIR can recruit PRC2 to their target genes [6,7]. Therefore, we examined whether ENST00000508435 affects migration in a similar manner. At first, RNA pull-down assay was performed with biotin labeled ENST00000508435 synthesized in vitro. Bands specific to ENST00000508435 were excised for mass spectrometry (Figure 3(a)). In addition to nonspecific binding proteins, FXR1 had the highest unique peptides in all proteins (Supplementary Table 2). Then we performed qPCR to seek the specific band (Figure 3(b)), and western blot (protein captured from RNA pull-down assays in BT549 cells) to verify the mass spectrometry result. FXR1 enriched by sense RNA compared with antisense RNA (Figure 3(c)). We further used cell extracts from BT549 cell lines to perform RNA immunoprecipitation (RIP) with an antibody against FXR1. RT-qPCR studies showed that ENST00000508435 was significantly enriched by the FXR1 antibody (Figure 3(d)). FXR1 expressed significantly higher in both breast
cancer cell lines (MCF10A versus BT549, MCF7, MDA-MB-231, MDA-MB-468 and T47D) and tissues (Figure 3(e,f)). Furthermore, we found that ENST00000508435 and FXR1 were positively correlated (Figure 3(g)).

**Knockdown of FXR1 inhibits the effects of ENST00000508435 on cell migration**

We investigated the role of ENST00000508435 on FXR1 function by ectopic expression of ENST00000508435 in MDA-MB-231 or down-regulation ENST00000508435 expression with ENST siRNA-homo-317 in MDA-MB-231 and BT549 cell lines. The expression of FXR1 was up-regulated or down-regulated when ENST00000508435 was over-expressed or knocked down (Figure 4(a,b)), respectively. In cell migration assay (MDA-MB-231 cell lines), the expression of FXR1 was knocked down (verified by RT-qPCR and western blot assay after 48 h transfection) (Figure 4(c,d)), which inhibited the effects of ENST00000508435 on cell migration and invasion through transwell (Figure 4(e)) and microfluidic chip invasion assay (Figure 4(f)). These findings suggested that FXR1 mediated the effect of ENST00000508435. We also analyzed the relationship between expression of FXR1 and clinical pathological parameters [tumor size, breast cancer biomarkers (ER, PgR and HER2), lymph node metastasis, ki67 and Nottingham grade], and found that the expression of FXR1 was positively correlated with lymph node metastasis (Supplementary Table 3).
Figure 2. ENST00000508435 (ENST for short) can promote migration of breast cancer cells. (a) RT-qPCR to detect the overexpression efficiency when pcDNA-ENST00000508435 plasmid were transfected into MDA-MB-231 cells. (b-c) After overexpression for 48 h, transwell assays and cell wound healing were carried out to detect cell migration (left panel), the right panel are the statistical charts. Scale bar is 200 μm. (d) Cell migration was assessed by wound scratch assay in the following 24 h in MDA-MB-231. (e) RT-qPCR to detect inhibition efficiency when down-regulating ENST00000508435 through siRNA in BT549 cells. siRNA-358, siRNA-317, siRNA-215 are three different interfering targets of ENST00000508435. (f-g) Cell migration detection when ENST00000508435 was knocked down. left panel, cell migration; right panel, statistical charts. Scale bar is 200 μm. Data are shown as the mean ±S.D. based on five independent experiments. *P< 0.05 versus control; **P< 0.01 versus control.
Figure 3. *ENST00000508435* (ENST for short) can bind to FXR1. (a) *ENST00000508435* specific combining proteins were detected by RNA pull down, and silver stain of the SDS-PAGE gel indicated the specific band was between 72 and 95 kDa as indicated by the red line, which was used for mass spectrometry. (b) After overexpression of *ENST00000508435* for 48 h in MDA-MB-231 cells, the mRNA level of FXR1 was higher than the control. (c) Western blot (BT549 cell lines) verified FXR1 can combine to biotinylated lncRNA *ENST00000508435*. (d) RIP experiments were executed using the FXR1 or IgG antibody to immunoprecipitate RNA and the purified RNA was used to detect *ENST00000508435* in BT549 cell, the enrichment of *ENST00000508435* was normalized to input. *P < 0.05 versus control; (e-f) RT-qPCR to detect the expression of FXR1 in five different breast cancer cell lines (e) (n = 5) and breast tissues (f). (g) The correlation analysis between *ENST00000508435* and FXR1 by SPSS. Data are shown as the mean ± S.D. (n = 5). *P < 0.05 versus control; ****P < 0.0001 versus control.
Figure 4. Knockdown of FXR1 abolished the effects of ENST00000508435 (ENST for short) on cell migration. (a) BT549 cells were transfected with siRNA-ENST00000508435, western blot to detect the FXR1 expression. (b) MDA-MB-231 cells were transfected with pcDNA-ENST00000508435, western blot to detect the FXR1 expression in 48 h and 72 h. (c and d) Western blot or RT-qPCR to detect the transfection efficiency of FXR1 in MDA-MB-231 cells. (e) After transfection of pcDNA-ENST00000508435 and siRNA-FXR1 for 48 h, transwell assays were carried out to detect cell migration of MDA-MB-231, scale bar is 200 μm. (f) Microfluidic chip invasion assay were carried out to detect cell invasion of MDA-MB-231. DAPI stained nucleus. Scale bar is 100 μm. Data show a representative of five independent experiments. Error bars indicate S.D. (n = 5). *P < 0.05 versus control; ***P < 0.001 versus control.
ENST00000508435 promotes breast cancer lung metastasis

To detect the in vivo metastatic ability of ENST00000508435 in breast cancer cells, we injected MDA-MB-231 cells, stably expressing ENST00000508435, and control cells, respectively, into BALB/c nude mice via the tail vein to compare the abilities of these cell lines of forming lung metastatic nodules. Accordingly, the number of metastatic nodules on the lung surfaces (Figure 5(a)) and metastatic foci after H&E staining (Figure 5(b,c)) in the mice that were injected with ENST00000508435-overexpressed cells was obviously more than that within control groups.

Discussion

The pathological development of breast cancer is related to the inactivation of tumor suppressor gene and abnormal molecular signaling pathway [8,9]. At the same time, the overexpression of oncogene is closely related to metastasis, recurrence, poor prognosis and short survival time. Benefit from the advancement of therapies (chemo, hormone, immuno and gene), long-term survival of breast cancer patients has become possible. However, up to 70% of lymph node positive patients tend to develop distant metastases, which is quite detrimental [10]. Early diagnosis biomarkers for breast cancer are mainly concentrated on protein coding genes, such as TBX2/3, Ki-67, HER-2, ER, VEGF and PR, among which HER2 protein expression is acknowledgedly related to metastasis and survival time. Thus, HER2 protein was chosen to judge the prognosis of breast cancer [11,12]. Compared with the protein coding genes, IncRNAs is relatively massive [11,12]. Recently, IncRNAs have been proved playing a critical role in tumorigenesis, and contributing to a diverse of biological functions in human cancers [13,14]. For example, HOTAIR is an early reported IncRNA, which regulates genes by chromosome remodeling [15]. Increased expression of HOTAIR in primary and metastatic breast cancer, especially of highly metastatic patients, is a significant predictor of subsequent metastasis and death [16]. In the current study, we found that the expression of IncRNA ENST0000508435, a novel transcript on chromosome 4, was greatly upregulated in breast cancer tissues and positively correlated with tumor size, lymph node metastasis and HER2 expression. This result suggests that ENST00000508435 may be involved in the pathogenesis of breast cancer.

Migration ability is a typical biological behavior of malignant tumor cells. More and more evidence reportedly support IncRNA as a prominent factor of regulating cancer cell migration and invasion. For example, the expression of LSN1CT5 in primary breast cancer tissues is ten times higher than that in normal tissues, which enhances the invasion of breast cancer cells via chemokine receptor (CXC4) [17]. In addition, IncRNA-MALAT1 and ZFX1 promoted the migration and invasion of lung cancer cells [17]. To investigate the biological role of ENST00000508435 in breast cancer, we assessed cell migration in both BT549 and MDA-MB-231 cells with transwell, wound healing and microfluidic chip invasion assay, and we found that ENST00000508435 remarkably promoted breast cancer cell migration. However, the detailed mechanism remains to be explored.

It is been reported that IncRNAs may impact on cellular functions through various mechanisms, such as protein-protein scaffolds, protein-DNA, protein decoys, miRNA sponges, and regulators of translation [13]. For instance, IncRNA Xist was responsible for recruiting PRC2 to specific genomic regions, and EZH2 served as the RNA-binding subunit [13]. In addition, the conserved A-repeat domain of IncRNA Xist could be identified by PRC2 complex protein EZH2 [18–20]. HOX cluster-derived IncRNA, HOTAIR, was validated to recruit PRC2 to its target gene [6,21]. Therefore, we hypothesized that ENST00000508435 was also regulated by related binding proteins. Performing RNA pull-down assay, mass spectrometry, western blot, and RIP, we identified that Fragile X-Related 1 gene (FXR1) was the specific binding protein of ENST00000508435.

FXR1 belongs to the RNA-binding proteins family, including Fragile X mental retardation-related gene 1 (FMR1) and Fragile X-related gene 2 (FXR2) [6,21]. RNA binding proteins (RBPs) are important molecules in the process of RNA metabolism, from synthesis to degradation. RBPs regulate RNA metabolism through RNA-protein and protein–protein interaction networks [22]. FXR1 combines with RNA and is involved in special diseases via RNA [23]. Jorge Bolivar showed us that FXR1 was involved in many biological processes of miRNA, which is essential for the maturation of miR-1, miR-124 and miR-9 [24]. A recent observation indicated IncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR-92a/FXR1 axis [24]. Additionally, Qihong Huang identified a novel ribonucleoprotein (RNP) complex (hnRNPK, FXR1, FXR2, PUF60, SF3B3), which is required for translational regulation of IncRNA to cause tumor invasion and metastasis [25]. In our study,
overexpression of ENST00000508435 significantly increased migration of MDA-MB-231 cells, which was inhibited by depletion of FXR1, supporting that the function of ENST00000508435 in breast cancer migration depends on FXR1. FXR1 may act as a target of ENST00000508435.

What we have done here indicated that ENST00000508435 participated in promoting migration...
of breast cancer by interacting with FXR1 (Figure 5(d)). Future investigations are needed to explore whether lncRNAs and RNA-binding proteins might serve as potential diagnostic and prognostic markers, or even novel therapeutic targets.

Conclusion

LncRNA takes a great part in tumor progression, and its definite role in breast cancer, a complicated disease with a high mortality rate, remains to be revealed. Here, our work shows that lncRNA ENST00000508435 significantly promotes breast cancer metastasis, and we initially report that the effect of ENST00000508435 is mediated by FXR1, which is co-expressed and positively correlated with ENST00000508435 in breast cancer cell lines and tissues. To sum up, ENST00000508435 and FXR1 may represent new biomarkers and potential targets for breast cancer clinical therapy.

Abbreviations

lncRNA, long non-coding RNA; RIP, RNA immunoprecipitation; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PBS, phosphate-buffered saline; RT-qPCR, Real-time quantitative PCR; FXR1, Fragile X mental retardation 1; XIST, X-inactive-specific transcript; EZH2, enhancer of zeste homolog 2; min, minute; h, hour.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by National Natural Science Foundation of China under Grant [81874121,81372849]; Natural Science Foundation of Shanghai under Grant [16ZR1403300].

ORCID

Ping Zhou https://orcid.org/0000-0002-4183-0639

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. DOI:10.3332/caac.21660
[2] Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1:391.
[3] Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. Rna Biol. 2013;10:925–933.
[4] Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15:43.
[5] Liao X-H, Wang J-G, Li L-Y, et al. Long intergenic non-coding RNA APOC1P1-3 inhibits apoptosis by decreasing α-tubulin acetylation in breast cancer. Cell Death Dis. 2016;7(5):e2236.
[6] Chu C, Qu K, Zhong FL, et al. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell. 2011;44:667–678.
[7] Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129:1311–1323.
[8] Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–463.
[9] Stevens RG, Brainard GC, Blask DE, et al. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 2014;64:207–218.
[10] Desantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. Ca A Cancer J Clinicians. 2014;64:52.
[11] Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol. 2016;13:487–503.
[12] Nayar U, Cohen O, Kapstad G, et al. Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019;51:207–216.
[13] Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.
[14] Grelet S, Link LA, Howley B, et al. A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol. 2017;19:1105–1115.
[15] Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–1076.
[16] Tao D, Zhang Z, Liu X, et al. LncRNA HOTAIR promotes the invasion and metastasis of oral squamous cell carcinoma through metastasis-associated gene 2. Mol Carcinog. 2020;59:353–364.
[17] Silva JM, Boczek NJ, Berres MW, et al. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biology. 2011;8(3):496.
[18] Kaneko S, Li G, Son J, et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev. 2010;24:2615–2620.
[19] Maenner S, Blaud M, Fouillen L, et al. 2-D structure of the A region of Xist RNA and its implication for PRC2 association. Plos Biol. 2010;8:e1000276.
[20] Kanhere A, Viiri K, Araujo CC, et al. Short RNAs are transcribed from repressed polycomb target genes and
interact with polycomb repressive complex-2. Mol Cell. 2010;38:675–688.

[21] Imai-Sumida M, Dasgupta P, Kulkarni P, et al. Genistein represses HOTAIR/chromatin remodeling pathways to suppress kidney cancer. Cell Physiol Biochem. 2020;54:53–70.

[22] Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15:829–845.

[23] Herman AB, Vrakas CN, Ray M, et al. FXR1 is an IL-19-responsive RNA-binding protein that destabilizes pro-inflammatory transcripts in vascular smooth muscle cells. Cell Rep. 2018;24:1176–1189.

[24] Xu XL, Zong R, Li Z, et al. FXR1P but not FMRP regulates the levels of mammalian brain-specific microRNA-9 and microRNA-124. J Neurosci. 2011;31:13705–13709.

[25] Gumireddy K, Li A, Yan J, et al. Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. Embo J. 2013;32:2672–2684.